Regenerative Medicine Company Poised for Product and Business Development Successes in the New Year
San Diego, CA (PRWEB) January 14, 2009-- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, announced today that David Bagley has joined the Company as President. Histogen welcomes Bagley following a year of rapid growth, with product launches, clinical evaluations and a new facility move on the horizon.
"With the launch of Histogen's first product, the creation of an aesthetics division, and talented new members joining the team in 2008, we've laid the groundwork for exciting progress in the coming year," said Dr. Gail Naughton, Histogen CEO and Chairman of the Board. "I am pleased to welcome David Bagley to Histogen, and believe his business experience and background in the field of tissue engineering will be a great asset to Histogen as we move forward."
David Bagley brings more than 20 years of cell biology and tissue engineering industry experience to Histogen. He has been a contributor to operational, scientific and engineering advancements in the development of several technologies including cell culture, tissue engineered and cell-based products for the treatment of multiple critical diseases, wound care and aesthetic product applications.
Most recently, Bagley served as Vice President and General Manager for Allergan Medical, Inc. with a focus on operations, technology, global distribution, quality and business disciplines. Prior to this, he held positions with Smith + Nephew/Advanced Tissue Sciences for over 12 years, where his latest position was Vice President of Technology and Logistics.
Previously, Bagley worked for Sigma Chemical Company where he was involved in the development and launch of several tissue culture product lines. Early in his career, he worked for Hy
Copyright©2009 Vocus, Inc.
All rights reserved